Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Next Previous
Trial Profile

A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talquetamab (Primary) ; Teclistamab (Primary) ; Programmed cell death 1 receptor antagonists
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms TRIMM-3
  • Sponsors Janssen Research & Development

Most Recent Events

  • 23 May 2025 Planned primary completion date changed from 30 Apr 2025 to 22 May 2025.
  • 28 Feb 2025 Planned End Date changed from 31 Mar 2026 to 3 May 2027.
  • 28 Feb 2025 Planned primary completion date changed from 28 Feb 2025 to 30 Apr 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top